Diagnostics play a crucial role in medicine as they are used to guide patient treatment thus contributing to public health initiatives and managing disease burden.
NBI’s Biotechnology Department currently manufactures seven diagnostic reagents used to diagnose malaria and one for hepatitis. Due to their robustness and specificity, NBI’s anti-HRPII and anti-Aldolase Monoclonal Antibodies (mAbs) are considered the best in class for malaria diagnosis particularly for Plasmodium falciparum. As a result, NBI has enjoyed a large share of the market as a major supplier to Rapid Diagnostic Tests (RDT) malaria manufacturers who have targeted the UN endorsed and internationally funded Roll Back Malaria programme.
Our recombinant proteins and monoclonal antibodies are produced in ISO 13485 accredited laboratories, through the integration of molecular biology, protein expression, purification techniques, cell culture and immunological technologies.
In addition to the above antibodies, we also produce:
ELISA kits for the screening of plasma-derived products against hepatitis B, tetanus, rabies, varicella-zoster and von Willebrand factor.
Rapid Rhesus typing test kits are produced and supplied to antenatal clinics around the country and are used to determine the Rhesus blood type status of pregnant women.